Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. (Nasdaq: TARA) on July 24, 2020, covering events occurring on July 20, 2020, and July 23, 2020. The filing primarily addresses significant changes to the Company's Board of Directors and executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resignation of Director: Scott Braunstein, M.D., resigned from the Board of Directors effective July 20, 2020. He previously served on the Audit Committee. The resignation was not due to any disagreement with the Company.
- Departure of Officer: Julio Casoy, M.D., is scheduled to cease employment as Chief Medical Officer effective August 3, 2020.
- Appointment of Director: Barry Flannelly, Pharm.D, MBA, was appointed as a Class III director on July 23, 2020, to fill the vacancy left by Dr. Braunstein. His term extends until the 2023 annual meeting.
- Audit Committee Change: Richard Levy, M.D., a current independent director, was appointed to the Audit Committee on July 23, 2020.
Compensation and Governance Details
Dr. Flannelly's compensation package includes:
- Cash Compensation: Annual cash compensation of $40,000, payable in quarterly installments and pro-rated based on days served.
- Stock Options:
- Option to purchase 18,000 shares vesting over three years in equal monthly installments.
- Option to purchase 8,250 shares vesting over one year in equal monthly installments, fully vested by the 2021 annual meeting.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Flannelly.
Investor Verification Checklist
- Verify the impact of the Chief Medical Officer departure on ongoing clinical trials or product development timelines.
- Confirm the qualifications and background of the new director, Barry Flannelly, and the new Audit Committee member, Richard Levy.
- Review the Company's press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for any changes to the Board composition or executive team resulting from these transitions.